Page last updated: 2024-11-04

spiperone and Substance Withdrawal Syndrome

spiperone has been researched along with Substance Withdrawal Syndrome in 19 studies

Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.

Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.

Research Excerpts

ExcerptRelevanceReference
" Concurrent lithium treatment also facilitated the degree of analgesic tolerance, and naloxone-induced withdrawal hypothermia."3.67Chronically administered morphine increases dopamine receptor sensitivity in mice. ( Martin, JR; Takemori, AE, 1986)
"4."1.28Dopamine D2 and muscarinic receptor binding characteristics in rat brain after withdrawal of subchronic fluphenazine and sulpiride treatment. ( Hietala, J; Röyttä, M; Syvälahti, E, 1989)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-199013 (68.42)18.7374
1990's4 (21.05)18.2507
2000's2 (10.53)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Voronina, TA1
Borlikova, GG1
Garibova, TL1
Proskuryakova, TV1
Petrichenko, OB1
Burd, SG1
Avakyan, GN1
Clow, A2
Theodorou, A2
Jenner, P2
Marsden, CD2
Stolz, JF1
Marsden, CA1
Middlemiss, DN1
Reddy, PL1
Thorat, SN1
Bhargava, HN2
Maggos, CE1
Tsukada, H1
Kakiuchi, T1
Nishiyama, S1
Myers, JE1
Kreuter, J1
Schlussman, SD1
Unterwald, EM1
Ho, A1
Kreek, MJ1
Joyce, JN1
Christie, MJ1
Overstreet, DH1
Puri, SK1
Spaulding, TC1
Mantione, CR1
Tabakoff, B1
Hoffman, PL1
Kirch, DG1
Taylor, TR1
Creese, I1
Xu, SX1
Wyatt, RJ1
May, T1
Hietala, J1
Syvälahti, E1
Röyttä, M1
Gulati, A1
Spain, JW1
Klingman, GI1
Hruska, RE1
Agid, Y1
Bonnet, AM1
Ruberg, M1
Javoy-Agid, F1
Carlson, KR1
Cooper, DO1
Martin, JR2
Takemori, AE2

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study[NCT00661674]10 participants (Actual)Interventional2008-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

OOWS Score

"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)

Interventionunits on a scale (OOWS Scale) (Mean)
Placebo3.5
Palonosetron1.0
Palonosetron + Hydroxyzine0

SOWS Score

"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)

Interventionunits on a scale (SOWS Scale) (Mean)
Placebo6.0
Palonosetron4.0
Palonosetron + Hydroxyzine3.5

Other Studies

19 other studies available for spiperone and Substance Withdrawal Syndrome

ArticleYear
Effect of nooglutil on benzodiazepine withdrawal syndrome and binding of 3H-spiperone with D2 receptors in rat striatum.
    Bulletin of experimental biology and medicine, 2002, Volume: 134, Issue:5

    Topics: Animals; Anti-Anxiety Agents; Corpus Striatum; Diazepam; Glutamates; In Vitro Techniques; Kinetics;

2002
Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    European journal of pharmacology, 1980, May-02, Volume: 63, Issue:2-3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Bindi

1980
Effect of chronic antidepressant treatment and subsequent withdrawal on [3H]-5-hydroxytryptamine and [3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour.
    Psychopharmacology, 1983, Volume: 80, Issue:2

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Butyrophenones; Cerebral Cortex; Humans; Male; Met

1983
Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal.
    Advances in biochemical psychopharmacology, 1980, Volume: 24

    Topics: Adenylyl Cyclases; Animals; Apomorphine; Brain; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced;

1980
Evidence for the behavioral supersensitivity of dopamine D2 receptors without receptor up-regulation in morphine-abstinent rats.
    Brain research, 1993, Apr-02, Volume: 607, Issue:1-2

    Topics: Animals; Behavior, Animal; Body Temperature; Brain Chemistry; Bromocriptine; Drug Tolerance; Kinetic

1993
Sustained withdrawal allows normalization of in vivo [11C]N-methylspiperone dopamine D2 receptor binding after chronic binge cocaine: a positron emission tomography study in rats.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1998, Volume: 19, Issue:2

    Topics: Analysis of Variance; Animals; Benzazepines; Brain; Carbon Radioisotopes; Cocaine; Male; Radioligand

1998
D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.
    Synapse (New York, N.Y.), 2001, Volume: 40, Issue:2

    Topics: Animals; Brain; Dopamine Antagonists; Drug Administration Schedule; Haloperidol; Iodine Radioisotope

2001
Sensitivity of morphine-tolerant rats to muscarinic and dopaminergic agonists: relation to tolerance or withdrawal.
    Psychopharmacology, 1979, Volume: 65, Issue:1

    Topics: Animals; Conditioning, Operant; Drug Tolerance; Humans; Male; Morphine Dependence; Parasympathomimet

1979
Dopamine antagonist binding: a significant decrease with morphine dependence in the rat striatum.
    Life sciences, 1978, Aug-14, Volume: 23, Issue:6

    Topics: Animals; Corpus Striatum; Dopamine Antagonists; Humans; Kinetics; Male; Morphine; Morphine Dependenc

1978
Development of functional dependence on ethanol in dopaminergic systems.
    The Journal of pharmacology and experimental therapeutics, 1979, Volume: 208, Issue:2

    Topics: Adenylyl Cyclases; Alcoholism; Animals; Corpus Striatum; Dopamine; Drug Tolerance; Ethanol; Humans;

1979
Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors.
    The Journal of pharmacy and pharmacology, 1992, Volume: 44, Issue:2

    Topics: Animals; Benzazepines; Corpus Striatum; Male; Nicotine; Rats; Rats, Inbred Strains; Receptors, Dopam

1992
Striatal dopamine D1-like receptors have higher affinity for dopamine in ethanol-treated rats.
    European journal of pharmacology, 1992, May-14, Volume: 215, Issue:2-3

    Topics: Animals; Benzazepines; Corpus Striatum; Dopamine; Ethanol; Male; Rats; Rats, Wistar; Receptors, Dopa

1992
Dopamine D2 and muscarinic receptor binding characteristics in rat brain after withdrawal of subchronic fluphenazine and sulpiride treatment.
    Progress in neuro-psychopharmacology & biological psychiatry, 1989, Volume: 13, Issue:1-2

    Topics: Animals; Cerebral Cortex; Corpus Striatum; Fluphenazine; Kinetics; Male; Quinuclidinyl Benzilate; Ra

1989
Brain and spinal cord 5-HT2 receptors of morphine-tolerant-dependent and -abstinent rats.
    European journal of pharmacology, 1989, Aug-22, Volume: 167, Issue:2

    Topics: Animals; Brain; Drug Tolerance; Kinetics; Male; Morphine; Morphine Dependence; Rats; Rats, Inbred St

1989
[3H]Spiperone binding in the rat striatum during the development of physical dependence on phencyclidine and after withdrawal.
    Neuroscience letters, 1985, Jul-04, Volume: 58, Issue:1

    Topics: Animals; Butyrophenones; Corpus Striatum; Male; Phencyclidine; Rats; Rats, Inbred Strains; Receptors

1985
Pathophysiology of L-dopa-induced abnormal involuntary movements.
    Psychopharmacology. Supplementum, 1985, Volume: 2

    Topics: Brain; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parki

1985
Morphine dependence and protracted abstinence: regional alterations in CNS radioligand binding.
    Pharmacology, biochemistry, and behavior, 1985, Volume: 23, Issue:6

    Topics: Animals; Brain Chemistry; Clonidine; Dihydroalprenolol; Male; Morphine Dependence; Radioligand Assay

1985
Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity.
    The Journal of pharmacology and experimental therapeutics, 1987, Volume: 241, Issue:1

    Topics: Animals; Apomorphine; Behavior, Animal; Drug Interactions; Drug Tolerance; Levorphanol; Lithium; Mal

1987
Chronically administered morphine increases dopamine receptor sensitivity in mice.
    European journal of pharmacology, 1986, Feb-18, Volume: 121, Issue:2

    Topics: Analgesia; Animals; Apomorphine; Behavior, Animal; Binding Sites; Brain; Drug Implants; Drug Toleran

1986